A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MA / myeloablative

[Related PubMed/MEDLINE]
Total Number of Papers: 73
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MA  (>> Co-occurring Abbreviation)
Long Form:   myeloablative
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy. CI, CIR, DFS, GVHD, HIDT, HR, OS, PBSCs, PTCy
2017 A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations. allo-HSCT, NMA, RIC
2017 Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: A single-center cohort study. allo-HSCT, BSI, CI, GNB, GPB, MDR, NMA
2016 Acute myeloid leukemia developing in a granulocyte colony-stimulating factor-mobilized stem cell donor: A case report and review of the literature. MUD, NMA, PBSC, rhG-CSF, SCT
2016 Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. FHCRC, HCT, NMA, NRM, OM
2016 Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen. allo-HSCT, AML, ATG, CMV, GVHD, GVL
2016 Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide. DRI
2016 Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. FSH, HCT, RIC
2016 The Incidence and Severity of Oral Mucositis among AllogeneicHematopoietic Stem Cell Transplantation Patients: A Systematic Review. GVHD, HSCT, NCI, OM, RE, RIC, WHO
10  2015 Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type. CI, RIC
11  2015 Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. AML, HCT, MRD, NMA, NRM, OS
12  2015 Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. ACT, DCs, HSCs, NMA
13  2014 In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors. ---
14  2014 Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. HSCT, NMA
15  2014 Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. CI, CLL, HCT, MSD, PFS, RIC, TRM
16  2014 Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. HSCT, MFC, MRD
17  2014 Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. allo-HCT, AML, CMV, RIC
18  2013 Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. allo-HCT, MCL, NRM, OS, PFS, RIC/NST
19  2013 An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution. GVHD, HRQoL, QOL, RIT, TRM
20  2013 Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. aGVHD, BMTs, CI, RIC
21  2013 Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. aGVHD, HHV-6, HSCT, NMA
22  2013 Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. allo-HCT, DLBCL, NRM, OS, PFS, RR
23  2013 Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning. NM
24  2013 Lung function and airway inflammation monitoring after hematopoietic stem cell transplantation. FeNO, HSCT, NMA
25  2013 Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. NMA, TMZ
26  2013 Umbilical cord blood transplantation in hematologic diseases in patients over 15 years old: long-term experience at the Pontificia Universidad Catolica de Chile. dUCB, GVHD, MUD, PFS, SUCB, TRM, UCB
27  2013 Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. aGVHD, BMT, cGVHD, DFS, GVHD, PT-CY, TBI, TRM
28  2012 Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. aGVHD, CIBMTR, ET, FHCRC, HCT, MF, PFS, PV, TRM
29  2012 Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. DFS, MDS, NMA, RIC
30  2012 What is the role of transplantation for indolent lymphoma? allo, auto, B-NHLs, GVHD, GVL, HCT, RI
31  2011 Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. HSCT, NMA
32  2011 Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. DPR, UCB, URD
33  2011 Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. ALC, CI, OS, PFS, RIC, RR, UCBT
34  2011 Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome. CR, MDS, NRM, RAEB, RC, SCT
35  2011 Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. CI, HCT, PBSC, RBC, RIC, UCB
36  2011 Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). CIBMTR, HCT, TBI
37  2010 A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. CI, CIBMTR, DLBCL, HCT, OS, PFS, RR, TRM
38  2010 An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. aGVHD, allo-SCT, AUC, cGVHD, HPLC, i.v, MMF, MPA, NMA, PK, ss
39  2010 Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. aGVHD, APCs, cGVHD, HCT, HMBG1, HR, NMA, OS, PFS, RRM, TRM
40  2010 Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. aGVHD, AML, ATG, BU, CBT, cGVHD, CY, Flu, GVHD, LFS, NRM, TNC
41  2010 High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. aGVHD, cGVHD, sBAFF, SCT
42  2010 Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. CMV, DFS, KIR, OS, RIC, TRM, UCBT
43  2010 Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. MBI, NMA, SCT
44  2010 Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants. HR, NMA, SCT
45  2010 Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease. aGVHD, CBT, NMA, PES, TRM
46  2010 Successful hematopoietic stem cell transplantation in 2 children with X-linked chronic granulomatous disease from their unaffected HLA-identical siblings selected using preimplantation genetic diagnosis combined with HLA typing. BM, HSCT, PGD, UCB, X-CGD
47  2010 The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. AML, ATG, BU, CI, DFS, Flu, GVHD, HR, HSCT, NRM, OS, TBI
48  2010 The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. BMT, GVM, HSCT, KIR, NK, OS, PBSCT, RFS, RIC, RR
49  2009 Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. aGVHD, BM, cGVHD, CI, CMML, CR, DFS, HSCT, MDS, MDS-NOS, MDS-U, NMA, OS, PBSC, RA, RCMD, RCMD-RS, TBI, TRM, UCB, URD
50  2009 Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. BM, IPDMA, PBSCs
51  2009 Defining the intensity of conditioning regimens: working definitions. HSCT, NMA, RIC, SC
52  2009 Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. DFS, GVHD, NMA, OS, RI, TRM
53  2009 Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. NMA, TRM
54  2009 Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. CI, HCT
55  2009 Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. allo-SCT, CMV, IRM, NRM, RIC, UCB, UCBT
56  2009 Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. aGVHD, ALL, CBT, cGVHD, CML, CR, GVL, MMURD, MRD, MURD, NIH, TRM
57  2009 Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graft-versus-host disease. CBT, CBT, CBU, OS, PES, TNC
58  2009 Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. CI, HCT, MDS, OS, RR, SES, TRM
59  2009 Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. aGVHD, allo-HSCT, CsA, CY, DFS, Flu, GVHD, OS, TBI
60  2009 Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens. HCT
61  2009 The evolution of hematopoietic SCT in myelodysplastic syndrome. allo-HCT, DFS, IPSS, MDS, MRD, MUD, NST, RIC, UCB, WPSS
62  2008 Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. GVHD, HCT, HR, NMA
63  2008 Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. NMA, OS, PFS, TRM
64  2008 Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. CI, CKD, GFR, HCT, RIC, RR
65  2007 Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. CC, MC, PCR, SCT
66  2007 Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation. HSCT, NMA, PRCA
67  2007 Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. AML, CR, DFS, MDS, non-MA, RR
68  2007 Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. AML, DFS, GVHD, HSCT, RI
69  2006 Allogeneic haematopoietic stem cell transplantation: current status and future outlook. allo-SCT, CB, DLIs, GVHD, MSC, PBSCs, RIC
70  2006 Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. ATG, EBV, NMA, PTLD, UCB
71  2005 Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). ALWP, AML, BU, EBMT, HSCT, RIC
72  2005 Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. AML, NMA, SCT
73  2004 Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. CMV, HLA, NMA, SCT